Intel (INTC) 10-Q31 Oct 242024 Q3 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares shares in Millions	9 Months Ended
Cover Page - shares shares in Millions	Sep. 28, 2024	Oct. 25, 2024
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 28, 2024
Entity File Number	000-06217
Entity Registrant Name	INTEL CORPORATION
Entity Central Index Key	0000050863
Current Fiscal Year End Date	--12-28
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-1672743
Entity Address, Address Line One	2200 Mission College Boulevard,
Entity Address, City or Town	Santa Clara,
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95054-1549
City Area Code	(408)
Local Phone Number	765-8080
Title of 12(b) Security	Common stock, $0.001 par value
Trading Symbol	INTC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		4,313

Consolidated Condensed Statemen

Consolidated Condensed Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Income Statement [Abstract]
Net revenue	$ 13,284	$ 14,158	$ 38,841	$ 38,822
Cost of sales	11,287	8,140	27,080	24,158
Gross margin	1,997	6,018	11,761	14,664
Research and development	4,049	3,870	12,670	12,059
Marketing, general, and administrative	1,383	1,340	4,268	4,017
Restructuring and other charges	5,622	816	6,913	1,080
Operating expenses	11,054	6,026	23,851	17,156
Operating income (loss)	(9,057)	(8)	(12,090)	(2,492)
Gains (losses) on equity investments, net	(159)	(191)	(74)	(46)
Interest and other, net	130	147	355	512
Income (loss) before taxes	(9,086)	(52)	(11,809)	(2,026)
Provision for (benefit from) taxes	7,903	(362)	7,271	(1,041)
Net income (loss)	(16,989)	310	(19,080)	(985)
Less: net income (loss) attributable to non-controlling interests	(350)	13	(450)	(5)
Net income (loss) attributable to Intel	$ (16,639)	$ 297	$ (18,630)	$ (980)
Earnings per share - Basic (in dollars per share)	$ (3.88)	$ 0.07	$ (4.37)	$ (0.23)
Earnings per share - Diluted (in dollars per share)	$ (3.88)	$ 0.07	$ (4.37)	$ (0.23)
Weighted average shares of common stock outstanding:
Basic (shares)	4,292	4,202	4,267	4,180
Diluted (shares)	4,292	4,229	4,267	4,180

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Statement of Comprehensive Income [Abstract]
Net income (loss)	$ (16,989)	$ 310	$ (19,080)	$ (985)
Changes in other comprehensive income, net of tax:
Net unrealized holding gains (losses) on derivatives	512	(320)	32	(310)
Actuarial valuation and other pension benefits (expenses), net	0	2	0	5
Translation adjustments and other	(1)	1	(2)	6
Other comprehensive income (loss)	511	(317)	30	(299)
Total comprehensive income (loss)	(16,478)	(7)	(19,050)	(1,284)
Less: comprehensive income (loss) attributable to non-controlling interests	(350)	13	(450)	(5)
Total comprehensive income (loss)	$ (16,128)	$ (20)	$ (18,600)	$ (1,279)

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Current assets:
Cash and cash equivalents	$ 8,785	$ 7,079
Short-term investments	15,301	17,955
Accounts receivable, net	3,121	3,402
Inventories	12,062	11,127
Other current assets	6,868	3,706
Total current assets	46,137	43,269
Property, plant, and equipment, net of accumulated depreciation of $101,124 ($98,010 as of December 30, 2023)	104,248	96,647
Equity Investments	5,496	5,829
Goodwill	24,680	27,591
Identified intangible assets, net	3,975	4,589
Other long-term assets	9,006	13,647
Total assets	193,542	191,572
Current liabilities:
Short-term debt	3,765	2,288
Accounts payable	11,074	8,578
Accrued compensation and benefits	5,015	3,655
Income taxes payable	2,440	1,107
Other accrued liabilities	12,865	12,425
Total current liabilities	35,159	28,053
Debt	46,471	46,978
Other long-term liabilities	7,048	6,576
Contingencies (Note 14)
Stockholders’ equity:
Common stock and capital in excess of par value, 4,313 issued and outstanding (4,228 issued and outstanding as of December 30, 2023)	50,665	36,649
Accumulated other comprehensive income (loss)	(185)	(215)
Retained earnings	49,052	69,156
Total stockholders' equity	99,532	105,590
Non-controlling interest	5,332	4,375
Accumulated other comprehensive income (loss)	104,864	109,965
Total liabilities and stockholders’ equity	$ 193,542	$ 191,572

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) shares in Millions, $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Assets
Accumulated depreciation	$ 101,124	$ 98,010
Stockholders’ equity:
Common stock, shares issued	4,309	4,228
Common stock, shares outstanding		4,228

Consolidated Condensed Statem_3

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023
Statement of Cash Flows [Abstract]
Cash and cash equivalents, beginning of period	$ 7,079	$ 11,144
Cash flows provided by (used for) operating activities:
Net income (loss)	(19,080)	(985)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation	7,651	5,753
Share-based compensation	2,759	2,433
Restructuring and other charges	3,626	718
Amortization of intangibles	1,081	1,336
(Gains) losses on equity investments, net	75	47
Deferred taxes	6,368	(1,376)
Impairments and net (gain) loss on retirement of property, plant, and equipment	2,290	(87)
Changes in assets and liabilities:
Accounts receivable	282	1,290
Inventories	(969)	1,758
Accounts payable	566	(1,082)
Accrued compensation and benefits	1,384	(1,171)
Income taxes	(930)	(1,300)
Other assets and liabilities	20	(487)
Total adjustments	24,203	7,832
Net cash provided by operating activities	5,123	6,847
Cash flows provided by (used for) investing activities:
Additions to property, plant and equipment	(18,110)	(19,054)
Proceeds from capital-related government incentives	725	649
Purchases of short-term investments	(31,519)	(37,287)
Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale	34,268	36,725
Other investing	144	244
Net cash used for investing activities	(14,492)	(18,723)
Cash flows provided by (used for) financing activities:
Issuance of commercial paper, net of issuance costs	7,349	0
Repayment of commercial paper	(7,349)	(3,944)
Payments on finance leases	0	(96)
Partner contributions	12,278	1,106
Proceeds from sales of subsidiary shares	0	2,423
Issuance of long-term debt, net of issuance costs	2,975	11,391
Repayment of debt	(2,288)	(423)
Proceeds from sales of common stock through employee equity incentive plans	986	1,037
Payment of dividends to stockholders	(1,599)	(2,561)
Other financing	(1,277)	(580)
Net cash provided by (used for) financing activities	11,075	8,353
Net increase (decrease) in cash and cash equivalents	1,706	(3,523)
Cash and cash equivalents, end of period	8,785	7,621
Non-cash supplemental disclosures:
Acquisition of property, plant, and equipment	6,595	5,234
Recognition of capital-related government incentives	2,211	514
Interest, net of capitalized interest	1,099	663
Income taxes, net of refunds	$ 1,880	$ 1,649

Consolidated Condensed Statem_4

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Stock and Capital in Excess of Par Value	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interest
Common stock, shares outstanding, beginning (in shares) at Dec. 31, 2022		4,137
Total stockholders' equity, beginning at Dec. 31, 2022	$ 103,286	$ 31,580	$ (562)	$ 70,405	$ 1,863
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(985)			(980)	(5)
Other comprehensive income (loss)	(299)		(299)
Net proceeds from partner contributions	3,166	$ 1,254			1,912
Employee equity incentive plans and other (in shares)		91
Employee equity incentive plans and other	1,037	$ 1,037
Share-based compensation	2,433	$ 2,330			103
Restricted stock unit withholdings (in shares)		(12)
Restricted stock unit withholdings	(391)	$ (548)		157
Cash dividends declared	(2,561)			(2,561)
Common stock, shares outstanding, ending (in shares) at Sep. 30, 2023		4,216
Total stockholders' equity, ending at Sep. 30, 2023	$ 105,686	$ 35,653	(861)	67,021	3,873
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cash dividends declared (in dollars per share)	$ 0.62
Common stock, shares outstanding, beginning (in shares) at Jul. 01, 2023		4,188
Total stockholders' equity, beginning at Jul. 01, 2023	$ 104,471	$ 34,330	(544)	67,231	3,454
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	310			297	13
Other comprehensive income (loss)	(317)		(317)
Net proceeds from partner contributions	759	$ 388			371
Employee equity incentive plans and other (in shares)		33
Employee equity incentive plans and other	372	$ 372
Share-based compensation	772	$ 737			35
Restricted stock unit withholdings (in shares)		(5)
Restricted stock unit withholdings	(156)	$ (174)		18
Cash dividends declared	(525)			(525)
Common stock, shares outstanding, ending (in shares) at Sep. 30, 2023		4,216
Total stockholders' equity, ending at Sep. 30, 2023	$ 105,686	$ 35,653	(861)	67,021	3,873
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cash dividends declared (in dollars per share)	$ 0.13
Common stock, shares outstanding, beginning (in shares) at Dec. 30, 2023	4,228	4,228
Total stockholders' equity, beginning at Dec. 30, 2023	$ 109,965	$ 36,649	(215)	69,156	4,375
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(19,080)			(18,630)	(450)
Other comprehensive income (loss)	30		30
Net proceeds from partner contributions	12,278	$ 11,012			1,266
Employee equity incentive plans and other (in shares)		96
Employee equity incentive plans and other	986	$ 986
Share-based compensation	2,759	$ 2,618			141
Restricted stock unit withholdings (in shares)		(15)
Restricted stock unit withholdings	(475)	$ (600)		125
Cash dividends declared	(1,599)			(1,599)
Common stock, shares outstanding, ending (in shares) at Sep. 28, 2024		4,309
Total stockholders' equity, ending at Sep. 28, 2024	$ 104,864	$ 50,665	(185)	49,052	5,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cash dividends declared (in dollars per share)	$ 0.38
Common stock, shares outstanding, beginning (in shares) at Jun. 29, 2024		4,276
Total stockholders' equity, beginning at Jun. 29, 2024	$ 120,434	$ 49,763	(696)	66,162	5,205
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(16,989)			(16,639)	(350)
Other comprehensive income (loss)	511		511
Net proceeds from partner contributions	417	$ 0			417
Employee equity incentive plans and other (in shares)		38
Employee equity incentive plans and other	355	$ 355
Share-based compensation	800	$ 740			60
Restricted stock unit withholdings (in shares)		(5)
Restricted stock unit withholdings	(128)	$ (193)		65
Cash dividends declared	(536)			(536)
Common stock, shares outstanding, ending (in shares) at Sep. 28, 2024		4,309
Total stockholders' equity, ending at Sep. 28, 2024	$ 104,864	$ 50,665	$ (185)	$ 49,052	$ 5,332
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cash dividends declared (in dollars per share)	$ 0.13

Consolidated Condensed Statem_5

Consolidated Condensed Statements of Stockholders' Equity (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Cash dividends declared (in dollars per share)	$ 0.13	$ 0.13	$ 0.38	$ 0.62

Basis of Presentation

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 28, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Note 1 : Basis of Presentation We prepared our interim Consolidated Condensed Financial Statements that accompany these notes in conformity with US GAAP, consistent in all material respects with those applied in our 2023 Form 10-K. We have made estimates and judgments affecting the amounts reported in our Consolidated Condensed Financial Statements and the accompanying notes. The actual results that we experience may differ materially from our estimates. The interim financial information is unaudited, and reflects all normal adjustments that are, in our opinion, necessary to provide a fair statement of results for the interim periods presented. This report should be read in conjunction with our 2023 Form 10-K where we include additional information on our critical accounting estimates, policies, and the methods and assumptions used in our estimates.

Operating Segments

Operating Segments	9 Months Ended
Operating Segments	Sep. 28, 2024
Segment Reporting [Abstract]
Operating Segments	Note 2 : Operating Segments We previously announced the implementation of our internal foundry operating model, which took effect in the first quarter of 2024, and creates a foundry relationship between our Intel Products business (collectively CCG, DCAI, and NEX) and our Intel Foundry business. Intel Products consists substantially of design and development of CPUs and related solutions for third party customers. Intel Foundry consists substantially of process engineering, manufacturing, and foundry services groups that provide manufacturing, test, and assembly services to our Intel Products business and to third party customers. Both businesses utilize marketing, sales, and other support functions. Our internal foundry model is a key component of our strategy and is designed to reshape our operational dynamics and drive greater transparency, accountability, and focus on costs and efficiency. We also previously announced our intent to operate Altera as a standalone business, with segment reporting beginning in the first quarter of 2024. Altera was previously included in our DCAI segment results. As a result of these changes, we modified our segment reporting in the first quarter of 2024 to align to this new operating model. All prior period segment data has been retrospectively adjusted to reflect the way our Chief Operating Decision Maker (CODM) internally receives information and manages and monitors our operating segment performance starting in fiscal year 2024. There are no changes to our consolidated financial statements for any prior periods. We organize our business as follows: ▪ Intel Products: ▪ C lient Computing Group (CCG) ▪ Data Center and AI (DCAI) ▪ Network and Edge (NEX) ▪ Intel Foundry ▪ All other ▪ A ltera ▪ M obileye ▪ Other CCG, DCAI, and Intel Foundry qualify as reportable operating segments. NEX, Altera, and Mobileye do not qualify as reportable operating segments; however, we have elected to disclose their results. When we enter into federal contracts, they are aligned to the sponsoring operating segment. The accounting policies applied to our segments follow those applied to Intel as a whole. A summary of the basis for which we report our operating segment revenues and operating margin is as follows: Intel Products: CCG, DCAI, and NEX ▪ Segment revenue: consists of revenues from third party customers. The Intel Products operating segments represent a substantial majority of Intel consolidated revenue and are derived from our principal products that incorporate various components and technologies, including a microprocessor and chipset, a stand-alone SoC, or a multichip package, which are based on Intel architecture. ▪ Segment expenses: consists of intersegment charges for product manufacturing and related services from Intel Foundry, external foundry and other manufacturing expenses, product development costs, allocated expenses as described below, and direct operating expenses. Intel Foundry ▪ Segment revenue : consists substantially of intersegment product and services revenue for wafer fabrication, substrates and other related products, and services sold to Intel Products, Altera, and certain other Intel internal businesses. We recognize intersegment revenue based on the completion of performance obligations. Product revenue is recognized upon delivery and transfer of ownership which is generally at the completion of wafer sorting. Backend service revenue is recognized upon the completion of assembly and test milestones, which approximates the recognition of revenue over the service period. Intersegment sales are recorded at prices that are intended to approximate market pricing. Intel Foundry also includes certain third party foundry and assembly and test revenues from external customers that were $67 million in the three months ended September 28, 2024 and $171 million in the first nine months of 2024, compared to $312 million in the three months ended September 30, 2023 and $661 million in the first nine months of 2023. ▪ Segment expenses: consists of direct expenses for technology development, product manufacturing and services provided by Intel Foundry to internal and external customers, allocated expenses as described below, and direct operating expenses. Direct expenses for product manufacturing includes excess capacity charges. All Other: Altera & Mobileye ▪ Segment revenue: consists of product revenues from third party customers. Altera revenue is derived from programmable semiconductors, primarily FPGAs, CPLDs, acceleration platforms, software, IP, and related products. Mobileye revenue is derived from advanced driver-assistance systems (ADAS) and autonomous driving technologies and solutions. ▪ Segment expenses: Altera expenses consist of intersegment charges for product manufacturing and related services from Intel Foundry, third party manufacturing expenses, allocated expenses as described below, and direct operating expenses. Mobileye expenses consists of third party direct expenses for product manufacturing and related services for the manufacturing of Mobileye products and direct operating expenses. Our "all other" category also consists of "other", which includes: ▪ results of operations from non-reportable segments not otherwise presented, and from start-up businesses that support our initiatives; and ▪ historical results of operations from divested businesses. We allocate operating expenses from our sales and marketing group to the Intel Products operating segments and allocate operating expenses from our finance and administration groups to all of our operating segments, except Mobileye. We estimate that the substantial majority of our consolidated depreciation expense was incurred by Intel Foundry in the first nine months of 2024 and 2023. Intel Foundry depreciation expense is substantially included in overhead cost pools and then combined with other costs, and subsequently absorbed into inventory as each product passes through the manufacturing process and is sold to Intel Products or other customers. As a result, it is impracticable to determine the total depreciation expense included as a component of each Intel Products operating segment's operating income (loss). We do not allocate to our operating segments corporate operating expenses that primarily consist of: ▪ restructuring and other charges; ▪ share-based compensation; ▪ certain impairment charges; and ▪ certain acquisition-related costs, including amortization and any impairment of acquisition-related intangibles and goodwill. We do not allocate to our operating segments non-operating items such as: ▪ gains and losses from equity investments; ▪ interest and other income; and ▪ income taxes. The CODM, who is our CEO, allocates resources to and assesses the performance of each operating segment using information about the operating segment's revenue and operating income (loss). Although the CODM uses operating income (loss) to evaluate the segments, operating costs included in one segment may benefit other segments. The measures regularly provided to and used by our CODM under our new operating model continue to evolve; currently, our CODM does not regularly review or receive discrete asset information by segment. Intersegment eliminations: Intersegment sales and related gross margin on inventory recorded at the end of the period or sold through to third party customers is eliminated for consolidation purposes. The Intel Products operating segments and Intel Foundry are meant to reflect separate fabless semiconductor and foundry companies, respectively. Thus, certain intersegment activity is captured within the intersegment eliminations upon consolidation and presented at the Intel consolidated level. This activity primarily relates to inventory reserves, which are determined and recorded based on our accounting policies for Intel as a whole but are only recorded by the Intel Products operating segments upon transfer of inventory from Intel Foundry. If a reserve is identified which relates to neither Intel Products operating segments nor Intel Foundry, the reserve is recognized as activity within the intersegment eliminations for Intel on a consolidated basis. Operating segment and consolidated net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Operating segment revenue: Intel Products: Client Computing Group Desktop $ 2,070 $ 2,753 $ 7,058 $ 7,002 Notebook 4,888 4,503 14,049 11,806 Other 372 611 1,166 1,606 7,330 7,867 22,273 20,414 Data Center and AI 3,349 3,076 9,430 9,132 Network and Edge 1,511 1,450 4,219 4,303 Total Intel Products revenue $ 12,190 $ 12,393 $ 35,922 $ 33,849 Intel Foundry $ 4,352 $ 4,732 $ 13,041 $ 13,735 All other Altera 412 735 1,115 2,399 Mobileye 485 530 1,164 1,442 Other 142 187 503 470 Total all other revenue 1,039 1,452 2,782 4,311 Total operating segment revenue $ 17,581 $ 18,577 $ 51,745 $ 51,895 Intersegment eliminations (4,297) (4,419) (12,904) (13,073) Total net revenue $ 13,284 $ 14,158 $ 38,841 $ 38,822 Segment operating income (loss): Intel Products: Client Computing Group $ 2,722 $ 2,780 $ 7,864 $ 5,946 Data Center and AI 347 391 1,105 882 Network and Edge 268 100 591 95 Total Intel Products operating income (loss) $ 3,337 $ 3,271 $ 9,560 $ 6,923 Intel Foundry $ (5,844) $ (1,407) $ (11,148) $ (5,636) All Other Altera 9 263 (55) 899 Mobileye 78 170 82 422 Other (42) (198) (229) (384) Total all other operating income (loss) $ 45 $ 235 $ (202) $ 937 Total segment operating income (loss) $ (2,462) $ 2,099 $ (1,790) $ 2,224 Intersegment eliminations (79) 5 124 48 Corporate unallocated expenses (6,516) (2,112) (10,424) (4,764) Total operating income (loss) $ (9,057) $ (8) $ (12,090) $ (2,492) Corporate Unallocated Expenses Corporate unallocated expenses include certain operating and non-operating costs not allocated to specific operating segments. The nature of these expenses may vary, but primarily consist of restructuring and other charges, share-based compensation, certain impairment charges, and certain acquisition-related costs. Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Acquisition-related costs $ (266) $ (344) $ (796) $ (1,065) Share-based compensation (800) (772) (2,759) (2,433) Restructuring and other charges 1 (5,622) (816) (6,913) (1,080) Other 172 (180) 44 (186) Total corporate unallocated expenses $ (6,516) $ (2,112) $ (10,424) $ (4,764) 1 See "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements for further information.

Non-Controlling Interests

Non-Controlling Interests	9 Months Ended
Non-Controlling Interests	Sep. 28, 2024
Noncontrolling Interest [Abstract]
Non-Controlling Interests	Note 3 : Non-Controlling Interests Sep 28, 2024 Dec 30, 2023 ($ In Millions) Non-Controlling Interests Non-Controlling Ownership % Non-Controlling Interests Non-Controlling Ownership % Ireland SCIP $ 51 49 % $ — — % Arizona SCIP 3,518 49 % 2,359 49 % Mobileye 1,617 12 % 1,838 12 % IMS Nanofabrication 146 32 % 178 32 % Total non-controlling interests $ 5,332 $ 4,375 Semiconductor Co-Investment Program Ireland SCIP In the second quarter of 2024, we closed a transaction with Apollo Global Management, Inc., involving the sale of 49% of our interest in an Irish limited liability company (Ireland SCIP) for net proceeds of $11.0 billion, substantially all of which increased our capital in excess of par value. Ireland SCIP is a VIE that we consolidate into our consolidated financial statements because we are the primary beneficiary. Generally, distributions will be received from Ireland SCIP based on both parties' proportional ownership. Ireland SCIP has the rights to operate Fab 34 in Leixlip, Ireland, and has the rights to the related factory output. We have the right to purchase 100% of the related factory output from Ireland SCIP. We will retain sole ownership of Fab 34, will be engaged as the Fab 34 operator in exchange for variable payments from Ireland SCIP based on the related factory output, and will be required to maintain certain performance standards in our capacity as operator. Once Fab 34 construction is complete, we will be required to purchase minimum quantities of the related factory output from Ireland SCIP, or we will be subject to pay certain penalties to Ireland SCIP. As of September 28, 2024, other than cash and cash equivalents held by Ireland SCIP, most of the remaining assets and liabilities of Ireland SCIP were eliminated in our consolidated financial statements. Arizona SCIP We consolidate the results of an Arizona limited liability company (Arizona SCIP), a VIE, into our consolidated financial statements because we are the primary beneficiary. Generally, contributions will be made to, and distributions will be received from Arizona SCIP based on both parties' proportional ownership. We will be the sole operator and main beneficiary of two new chip factories that will be constructed by Arizona SCIP, and we will have the right to purchase 100% of the related factory output. Once production commences, we will be required to operate Arizona SCIP at minimum production levels measured in wafer starts per week and will be required to limit excess inventory held on site or we will be subject to certain penalties. We have an unrecognized commitment to fund our respective share of the total construction costs of Arizona SCIP of $29.0 billion. As of September 28, 2024, substantially all of the assets of Arizona SCIP consisted of property, plant, and equipment. The remaining assets and liabilities of Arizona SCIP were eliminated in our consolidated financial statements. The assets held by Arizona SCIP, which can be used only to settle obligations of the VIE and are not available to us, were $9.3 billion as of September 28, 2024 ($4.8 billion as of December 30, 2023). Mobileye In 2022, Mobileye completed its IPO and certain other equity financing transactions. During 2023, we converted 38.5 million of our Mobileye Class B shares into Class A shares, representing 5% of Mobileye's outstanding capital stock, and subsequently sold the Class A shares for $42 per share as part of a secondary offering, receiving net proceeds of $1.6 billion and increasing our capital in excess of par value by $663 million, net of tax. We continue to consolidate the results of Mobileye into our consolidated financial statements. In the third quarter of 2024, the non-cash impairment of goodwill related to our Mobileye reporting unit was attributed to Intel and to non-controlling interest holders based on our proportional ownership (see "Note 10: Goodwill" within Notes to Consolidated Condensed Financial Statements). IMS Nanofabrication

Earnings Per Share

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 28, 2024
Earnings Per Share [Abstract]
Earnings Per Share	Note 4 : Earnings (Loss) Per Share We computed basic earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding during the period. We computed diluted earnings (loss) per share of common stock based on the weighted average number of shares of common stock outstanding plus potentially dilutive shares of common stock outstanding during the period. Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Net income (loss) $ (16,989) $ 310 $ (19,080) $ (985) Less: net income (loss) attributable to non-controlling interests (350) 13 (450) (5) Net income (loss) attributable to Intel $ (16,639) $ 297 $ (18,630) $ (980) Weighted average shares of common stock outstanding—basic 4,292 4,202 4,267 4,180 Dilutive effect of employee equity incentive plans — 27 — — Weighted average shares of common stock outstanding—diluted 4,292 4,229 4,267 4,180 Earnings (loss) per share attributable to Intel—basic $ (3.88) $ 0.07 $ (4.37) $ (0.23) Earnings (loss) per share attributable to Intel—diluted $ (3.88) $ 0.07 $ (4.37) $ (0.23) Potentially dilutive shares of common stock from employee equity incentive plans are determined by applying the treasury stock method to the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, and the assumed issuance of common stock under the stock purchase plan. The potentially dilutive impact from the assumed issuance of common stock associated with the contractual conversion feature is determined by applying the if-converted method to the assumed exercise of the outstanding conversion feature. In the three and nine months ended September 28, 2024 and in the nine months ended September 30, 2023, the assumed exercise of outstanding stock options, the assumed vesting of outstanding RSUs, the assumed issuance of common stock under the stock purchase plan, and the assumed issuance of common stock associated with a contractual conversion feature, as applicable, had an anti-dilutive effect on diluted loss per share and were excluded from the computation of diluted loss per share. During the three months ended September 28, 2024, 160 million anti-dilutive shares were excluded from the computation of diluted earnings per share. In all other periods presented, securities that would have been anti-dilutive were insignificant.

Other Financial Statement Detai

Other Financial Statement Details	9 Months Ended
Other Financial Statement Details	Sep. 28, 2024
Other Financial Statement Details [Abstract]
Other Financial Statement Details	Note 5 : Other Financial Statement Details Accounts Receivable We sell certain of our accounts receivable on a non-recourse basis to third-party financial institutions. We record these transactions as sales of receivables and present cash proceeds as cash provided by operating activities in the Consolidated Condensed Statements of Cash Flows. Accounts receivable sold under non-recourse factoring arrangements were $1.5 billion during the first nine months of 2024 and 2023. After the sale of our accounts receivable, we expect to collect payment from the customers and remit it to the third-party financial institution. Inventories (In Millions) Sep 28, 2024 Dec 30, 2023 Raw materials $ 1,434 $ 1,166 Work in process 6,971 6,203 Finished goods 3,657 3,758 Total inventories $ 12,062 $ 11,127 Property, Plant, and Equipment We invest in and deploy manufacturing assets in response to manufacturing capacity requirements based upon short- and long-term demand forecasts and economic returns relative to capital outlays. We regularly monitor, evaluate, and adjust our manufacturing capacity footprint in response to a number of volatile factors that impact our business, including demand for our products and services and the state of the semiconductor industry as a whole. In connection with the preparation of our Consolidated Condensed Financial Statements for the third quarter of 2024, we evaluated our current process technology node capacities relative to projected market demand for our products and services, concluding that our manufacturing asset portfolio, primarily for our Intel 7 process node, exceeded manufacturing capacity requirements. Upon performing a re-use assessment, we impaired and accelerated depreciation for certain manufacturing assets. In total, we recorded non-cash impairments and accelerated depreciation charges of $2.1 billion and $945 million, respectively, in the third quarter of 2024, substantially all of which were recognized in cost of sales within our Intel Foundry operating segment. We also incurred certain other non-cash asset impairment charges of $442 million as a direct result of the 2024 Restructuring Plan (see "Note 6: Restructuring and Other Charges" within Notes to Consolidated Condensed Financial Statements). These charges were included as a component of "corporate unallocated expenses" within the restructuring and other category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. Coinciding with the analysis described above and due to the reduction in our market capitalization relative to the net book value of our assets, we tested our asset groupings for impairment. As a result of that testing, which evaluated whether the carrying value of our asset group is recoverable through the related undiscounted cash flows, we concluded that the remaining carrying value of property, plant, and equipment is recoverable as of September 28, 2024. Other Accrued Liabilities Other accrued liabilities include deferred compensation of $3.2 billion as of September 28, 2024 ($2.9 billion as of December 30, 2023). Interest and Other, Net Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Interest income $ 340 $ 332 $ 983 $ 979 Interest expense (248) (204) (800) (611) Other, net 38 19 172 144 Total interest and other, net $ 130 $ 147 $ 355 $ 512 Interest expense is net of $392 million of interest capitalized in the third quarter of 2024 and $1.1 billion in the first nine months of 2024 ($395 million in the third quarter of 2023 and $1.1 billion in the first nine months of 2023).

Restructuring and Other Charges

Restructuring and Other Charges	9 Months Ended
Restructuring and Other Charges	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Restructuring and Other Charges	Note 6 : Restructuring and Other Charges Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Employee severance and benefit arrangements $ 2,193 $ 59 $ 2,487 $ 191 Litigation charges and other 36 757 814 854 Asset impairment charges 3,393 — 3,612 35 Total restructuring and other charges $ 5,622 $ 816 $ 6,913 $ 1,080 In the third quarter of 2024, the 2024 Restructuring Plan was announced, subsequently approved and committed to by our management team, and initiated to implement cost-reduction measures, including reductions in employee headcount, other operating and non-operating expenditures, and capital expenditures. Restructuring charges are primarily comprised of employee severance and benefit arrangements, non-cash charges related to asset impairments associated with exit activities, as well as charges relating to real estate exits and consolidations. These charges were included as "corporate unallocated expenses" within the restructuring and other category presented in "Note 2: Operating Segments" within Notes to Consolidated Condensed Financial Statements. We expect to recognize total charges of approximately $3.0 billion under the 2024 Restructuring Plan, the substantial majority of which will be cash settled in future periods. The cumulative cost of the 2024 Restructuring Plan as of September 28, 2024 was $2.8 billion. Any changes to our estimates or timing will be reflected in our results of operations in future periods. We expect actions pursuant to the 2024 Restructuring Plan to be substantially complete by the fourth quarter of 2025, which is subject to change. Employee severance and benefit arrangements includes charges of $2.2 billion in the third quarter of 2024 relating to the 2024 Restructuring Plan. Charges relating to other actions taken to streamline operations and to reduce costs were $294 million in the nine months ended September 28, 2024, which we expect will be substantially complete by the fourth quarter of 2024. We expect employee severance and benefit-related actions resulting from our 2024 Restructuring Plan to be substantially complete by the fourth quarter of 2025, which is subject to change. Charges accrued as of September 28, 2024 were recorded as current liabilities within accrued compensation and benefits on the Consolidated Condensed Balance Sheets . Charges in the three and nine months ended September 30, 2023 primarily related to the 2022 Restructuring Program, which was completed in the first quarter of 2024. Litigation charges and other includes a charge of $780 million in the second quarter of 2024 arising out of the R2 litigation. In the third quarter of 2023, we recorded a $401 million charge for an EC-imposed fine. Refer to "Note 14: Contingencies" within Notes to Consolidated Condensed Financial Statements for information about these items. Also, in the third quarter of 2023, we incurred and paid a termination fee of $353 million in connection with our inability to timely obtain required regulatory approvals needed to acquire Tower Semiconductor, Ltd. (Tower). Asset impairment charges in the third quarter of 2024 primarily includes cash and non-cash charges associated with the 2024 Restructuring Plan, including $442 million of non-cash impairments of construction in progress assets associated with our decision to exit and outsource manufacturing capabilities for certain internal test hardware; and $86 million of non-cash impairments of operating leased assets and related leasehold improvements resulting from real estate consolidations and exits. Real estate consolidations and exits did not materially change our operating lease liabilities and may result in future cash outlays for facility restoration or the relocation of operations. These impairments were recorded within property, plant, and equipment, net of accumulated depreciation, except for the impairment of operating leased assets of $72 million which were recorded within other long-term assets on the Consolidated Condensed Balance Sheets as of September 28, 2024. In addition, we recorded non-cash goodwill impairment charges of $2.8 billion and $3.0 billion in the three and nine months ended September 28, 2024, respectively (see "Note 10: Goodwill" within Notes to Consolidated Condensed Financial Statements). Further, in the third quarter of 2024, as a result of a decline in the actual and projected undiscounted cash flows for certain acquired intangible assets, we concluded the assets were not recoverable and recognized a non-cash impairment charge of $108 million. Goodwill and intangible asset impairment charges were included as "corporate unallocated expenses" within the restructuring and other

Income Taxes

Income Taxes	9 Months Ended
Income Taxes	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Income Taxes	Note 7 : Income Taxes Three Months Ended Nine Months Ended ($ In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Income (loss) before taxes $ (9,086) $ (52) $ (11,809) $ (2,026) Provision for (benefit from) taxes $ 7,903 $ (362) $ 7,271 $ (1,041) Effective tax rate (87.0) % 696.2 % (61.6) % 51.4 % In the three and nine months ended September 28, 2024, we established a valuation allowance of $9.9 billion as a discrete non-cash tax expense against our US deferred tax assets. We assess the recoverability of our deferred tax assets quarterly, weighing available positive and negative evidence. As a result of our assessment in the third quarter of 2024, we determined it is more likely than not that the deferred tax assets will not be recoverable based upon our three-year cumulative historical loss position as of September 28, 2024, largely resulting from the asset impairment and restructuring and other charges incurred during the current quarter. Deferred tax liabilities of $1.7 billion and $186 million were included within other long-term liabilities on the Consolidated Condensed Balance Sheets as of September 28, 2024 and December 30, 2023, respectively, and deferred tax assets of $634 million and $5.5 billion were included within other long-term assets on the Consolidated Condensed Balance Sheets as of of September 28, 2024 and December 30, 2023, respectively.

Investments

Investments	9 Months Ended
Investments	Sep. 28, 2024
Investments, Debt and Equity Securities [Abstract]
Investments	Note 8 : Investments Short-term Investments Short-term investments include marketable debt investments in corporate debt, government debt, and financial institution instruments, and are recorded within cash and cash equivalents and short-term investments on the Consolidated Condensed Balance Sheets . Government debt includes instruments such as non-US government bills and bonds and US agency securities. Financial institution instruments include instruments issued or managed by financial institutions in various forms, such as commercial paper, fixed- and floating-rate bonds, money market fund deposits, and time deposits. As of September 28, 2024 and December 30, 2023, substantially all time deposits were issued by institutions outside the US. For certain of our marketable debt investments, we economically hedge market risks at inception with a related derivative instrument or the marketable debt investment itself is used to economically hedge currency exchange rate risk from remeasurement. These hedged investments are reported at fair value with gains or losses from the investments and the related derivative instruments recorded in interest and other, net . The fair value of our hedged investments was $14.9 billion as of September 28, 2024 ($17.1 billion as of December 30, 2023). For hedged investments still held at the reporting date, we recorded net gains of $406 million in the third quarter of 2024 and net gains of $195 million in the first nine months of 2024 ($329 million of net losses in the third quarter of 2023 and $336 million of net losses in the first nine months of 2023). Our remaining unhedged marketable debt investments are reported at fair value, with unrealized gains or losses, net of tax, recorded in accumulated other comprehensive income (loss) and realized gains or losses recorded in interest and other, net . The adjusted cost of our unhedged investments was $5.2 billion as of September 28, 2024 ($4.7 billion as of December 30, 2023), which approximated the fair value for these periods. The fair value of marketable debt investments, by contractual maturity, as of September 28, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 7,508 Due in 1–2 years 2,322 Due in 2–5 years 6,537 Due after 5 years 215 Instruments not due at a single maturity date 1 3,544 Total $ 20,126 1 Instruments not due at a single maturity date is comprised of money market fund deposits, which are classified as either short-term investments or cash and cash equivalents. Equity Investments (In Millions) Sep 28, 2024 Dec 30, 2023 Marketable equity securities 1 $ 980 $ 1,194 Non-marketable equity securities 4,513 4,630 Equity method investments 3 5 Total $ 5,496 $ 5,829 1 Most of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange. The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Ongoing mark-to-market adjustments on marketable equity securities $ (51) $ (267) $ (185) $ (164) Observable price adjustments on non-marketable equity securities — 7 49 17 Impairment charges (110) (53) (269) (127) Sale of equity investments and other 1 2 122 331 228 Total gains (losses) on equity investments, net $ (159) $ (191) $ (74) $ (46) 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Divestitures

Divestitures	9 Months Ended
Divestitures	Sep. 28, 2024
Business Combinations [Abstract]
Divestitures	Note 9 : Divestitures NAND Memory Business We sold our NAND memory technology and manufacturing business (the NAND OpCo Business) to SK hynix Inc. (SK hynix) which we deconsolidated upon closing the first phase of the transaction on December 29, 2021. We have a receivable within other current assets for the transaction's remaining proceeds of $2.0 billion, which remains outstanding as of September 28, 2024 and will be received upon the second closing of the transaction, expected to be in March 2025. In connection with the transaction, we have a wafer manufacturing and sale agreement that includes incentives and penalties that are contingent on the cost of operation and output of the NAND OpCo Business. These incentives and penalties present a maximum exposure of up to $500 million annually, and $1.5 billion in the aggregate. We are currently in negotiations with SK hynix to update the operating plan of the NAND OpCo Business, which may impact the metrics associated with the incentives and penalties and our expectations of the performance of the NAND OpCo Business against those metrics. We were reimbursed for costs that we incurred on behalf of the NAND OpCo Business for corporate function services, which include human resources, information technology, finance, supply chain, and other compliance requirements. We recorded a receivable related to these reimbursable costs due from the NAND OpCo Business, a deconsolidated entity, of $92 million within other current assets as of September 28, 2024 ($145 million recorded as of December 30, 2023).

Goodwill

Goodwill	9 Months Ended
Goodwill	Sep. 28, 2024
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill	Note 10 : Goodwill Our quarterly qualitative impairment assessment for the third quarter of 2024 indicated that a more detailed quantitative analysis was necessary for certain of our reporting units, primarily due to the decline in our market capitalization below the carrying value of our net assets, as well as the decline in our Mobileye reporting unit's market capitalization below the carrying value of Mobileye's net assets. Our quantitative assessment was performed by measuring each reporting unit's fair value using either the income approach, the market approach, or a combination of both. When using the income approach, we tested the reasonableness of the inputs and outcomes of our discounted cash flow analysis against available market data. As a result of our impairment tests, we recognized a non-cash goodwill impairment charge of $2.8 billion in the third quarter of 2024 within restructuring and other, most of which related to our Mobileye reporting unit, as the estimated fair value of the reporting unit was lower than the assigned carrying value. The process of valuing each reporting unit is inherently subjective as valuation models require the application of significant estimates and the use of unobservable inputs, including market segment share, projected financial information, and discount rates. No impairment was required for our other reporting units, even when considering a hypothetical increase in the discount rate of 1%, which would cause a material decrease in the estimated fair value of the respective non-impaired reporting units. Finally, to corroborate our estimated fair value, we performed a market capitalization reconciliation as of September 28, 2024, concluding that the implied control premium was reasonable. In the first quarter of 2024, as a result of modifying our segment reporting, we reallocated goodwill among our affected reporting units on a relative fair value basis. We performed a quantitative goodwill impairment assessment for each of our reporting units immediately before and after our business reorganization. We concluded based on our pre-reorganization impairment test that goodwill was not impaired. As a result of our post-reorganization impairment test, we recognized a non-cash goodwill impairment loss of $222 million in the first quarter of 2024 related to our Intel Foundry reporting unit as the estimated fair value of the new reporting unit was lower than the assigned carrying value, which now includes substantially all of our allocated property, plant, and equipment. The Intel Foundry reporting unit has no remaining goodwill. At the conclusion of our impairment assessment performed during the first quarter of 2024, the fair value substantially exceeded the carrying value for all remaining reporting units.

Borrowings

Borrowings	9 Months Ended
Borrowings	Sep. 28, 2024
Debt Disclosure [Abstract]
Borrowings	Note 11 : Borrowings In the second quarter of 2024, we remarketed $438 million aggregate principal amount of bonds issued by the Industrial Development Authority of the City of Chandler, Arizona. In accordance with loan agreements we entered into with the Industrial Development Authority of the City of Chandler, Arizona, the bonds are unsecured general obligations. The bonds mature in 2049 and have a 4.00% coupon. The bonds are subject to optional tender starting in February 2029 and mandatory tender in June 2029, at which time we may remarket the bonds for a new term period. In the first quarter of 2024, we issued a total of $2.6 billion aggregate principal amount of senior notes comprised of $500 million in 5.00% senior notes due 2031, $900 million in 5.15% senior notes due 2034 and $1.2 billion in 5.60% senior notes due 2054. All of our senior fixed rate notes pay interest semiannually. We may redeem the fixed rate notes prior to their maturity at our option at specified redemption prices and subject to certain restrictions. The obligations under our senior fixed rate notes rank equally in the right of payment with all of our other existing and future senior unsecured indebtedness and effectively rank junior to all liabilities of our subsidiaries. In the first quarter of 2024, we expanded both our 5-year $5.0 billion revolving credit facility agreement and our 364-day $5.0 billion credit facility agreement, to $7.0 billion and $8.0 billion, respectively, and the maturity dates were extended by one year to February 2029 and January 2025, respectively. These credit facilities are unsecured general obligations. The revolving credit facilities had no borrowings outstanding as of September 28, 2024 and December 30, 2023 . We have an ongoing authorization from our Board of Directors to borrow up to $10.0 billion under our commercial paper program. In the first nine months of 2024, we borrowed $7.3 billion and settled in cash $7.3 billion of our commercial paper and had no commercial paper outstanding as of September 28, 2024 and December 30, 2023 . Borrowings under the commercial paper program are unsecured general obligations.

Fair Value

Fair Value	9 Months Ended
Fair Value	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Fair Value	Note 12 : Fair Value Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 28, 2024 Dec 30, 2023 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 213 $ — $ 213 $ — $ 769 $ — $ 769 Financial institution instruments¹ 3,415 1,197 — 4,612 2,241 835 — 3,076 Reverse repurchase agreements — 3,295 — 3,295 — 2,554 — 2,554 Short-term investments: Corporate debt — 5,777 — 5,777 — 6,951 — 6,951 Financial institution instruments¹ 129 3,301 — 3,430 33 4,215 — 4,248 Government debt² 20 6,074 — 6,094 — 6,756 — 6,756 Other current assets: Derivative assets 261 653 — 914 366 809 — 1,175 Marketable equity securities 980 — — 980 1,194 — — 1,194 Other long-term assets: Derivative assets — 5 — 5 — 21 — 21 Total assets measured and recorded at fair value $ 4,805 $ 20,515 $ — $ 25,320 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 457 $ 96 $ 553 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities — 212 — 212 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 669 $ 96 $ 765 $ — $ 1,020 $ 99 $ 1,119 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, commercial paper, notes, and bonds issued by financial institutions. 2 Level 1 investments consist of US Treasury securities. Level 2 investments consist primarily of non-US government debt. Assets Measured and Recorded at Fair Value on a Non-Recurring Basis Our non-marketable equity securities, equity method investments, and certain non-financial assets—such as intangible assets, goodwill, and property, plant, and equipment—are recorded at fair value only if an impairment or observable price adjustment is recognized in the current period. If an observable price adjustment or impairment is recognized on our non-marketable equity securities during the period, we classify these assets as Level 3. Similarly, impairments recognized on our goodwill, intangible assets, and property, plant, and equipment are categorized as Level 3 within the fair value hierarchy as we utilize unobservable inputs such as prospective financial information, market segment growth rates, and discount rates in the fair value measurement process. Financial Instruments Not Recorded at Fair Value on a Recurring Basis Financial instruments not recorded at fair value on a recurring basis include non-marketable equity securities and equity method investments that have not been remeasured or impaired in the current period, grants receivable, certain other receivables, and issued debt. We classify the fair value of grants receivable as Level 2. The estimated fair value of these financial instruments approximates their carrying value. The aggregate carrying value of grants receivable as of September 28, 2024 was $1.1 billion (the aggregate carrying value as of December 30, 2023 was $559 million).

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
Derivative Financial Instruments	Sep. 28, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Note 13 : Derivative Financial Instruments Volume of Derivative Activity Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Sep 28, 2024 Dec 30, 2023 Foreign currency contracts $ 28,674 $ 30,064 Interest rate contracts 18,105 18,363 Other 2,539 2,103 Total $ 49,318 $ 50,530 The total notional amount of outstanding pay-variable, receive-fixed interest rate swaps was $12.0 billion as of September 28, 2024 and December 30, 2023. Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Sep 28, 2024 Dec 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 290 $ 54 $ 255 $ 142 Interest rate contracts — 353 — 578 Total derivatives designated as hedging instruments $ 290 $ 407 $ 255 $ 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 224 $ 252 $ 314 $ 363 Interest rate contracts 144 106 261 36 Equity contracts 261 — 366 — Total derivatives not designated as hedging instruments $ 629 $ 358 $ 941 $ 399 Total derivatives $ 919 $ 765 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. Amounts Offset in the Consolidated Condensed Balance Sheets Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 767 $ — $ 767 $ (319) $ (448) $ — Reverse repurchase agreements 3,295 — 3,295 — (3,295) — Total assets $ 4,062 $ — $ 4,062 $ (319) $ (3,743) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 737 $ — $ 737 $ (319) $ (331) $ 87 Total liabilities $ 737 $ — $ 737 $ (319) $ (331) $ 87 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 We obtain and secure available collateral from counterparties against obligations, including securities lending transactions and reverse repurchase agreements, when we deem it appropriate. Derivatives in Cash Flow Hedging Relationships The before-tax net gains or losses attributed to cash flow hedges recognized in other comprehensive income (loss) were $609 million net gains in the third quarter of 2024 and $49 million net losses in the first nine months of 2024 ($454 million net losses in the third quarter of 2023 and $646 million net losses in the first nine months of 2023). Substantially all of our cash flow hedges were foreign currency contracts for all periods presented. During the first nine months of 2024 and 2023, the amounts excluded from effectiveness testing were insignificant. Derivatives in Fair Value Hedging Relationships The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Interest rate contracts $ 345 $ (168) $ 225 $ (189) Hedged items (345) 168 (225) 189 Total $ — $ — $ — $ — The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 28, 2024 Dec 30, 2023 Sep 28, 2024 Dec 30, 2023 Long-term debt $ (11,644) $ (11,419) $ 353 $ 578 Derivatives Not Designated as Hedging Instruments The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Foreign currency contracts Interest and other, net $ (344) $ 255 $ 192 $ 467 Interest rate contracts Interest and other, net (127) 85 24 175 Other Various 97 (112) 290 103 Total $ (374) $ 228 $ 506 $ 745

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (16,639)	$ 297	$ (18,630)	$ (980)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 28, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Operating Segments (Tables)

Operating Segments (Tables)	9 Months Ended
Operating Segments (Tables)	Sep. 28, 2024
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	Operating segment and consolidated net revenue and operating income (loss) for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Operating segment revenue: Intel Products: Client Computing Group Desktop $ 2,070 $ 2,753 $ 7,058 $ 7,002 Notebook 4,888 4,503 14,049 11,806 Other 372 611 1,166 1,606 7,330 7,867 22,273 20,414 Data Center and AI 3,349 3,076 9,430 9,132 Network and Edge 1,511 1,450 4,219 4,303 Total Intel Products revenue $ 12,190 $ 12,393 $ 35,922 $ 33,849 Intel Foundry $ 4,352 $ 4,732 $ 13,041 $ 13,735 All other Altera 412 735 1,115 2,399 Mobileye 485 530 1,164 1,442 Other 142 187 503 470 Total all other revenue 1,039 1,452 2,782 4,311 Total operating segment revenue $ 17,581 $ 18,577 $ 51,745 $ 51,895 Intersegment eliminations (4,297) (4,419) (12,904) (13,073) Total net revenue $ 13,284 $ 14,158 $ 38,841 $ 38,822 Segment operating income (loss): Intel Products: Client Computing Group $ 2,722 $ 2,780 $ 7,864 $ 5,946 Data Center and AI 347 391 1,105 882 Network and Edge 268 100 591 95 Total Intel Products operating income (loss) $ 3,337 $ 3,271 $ 9,560 $ 6,923 Intel Foundry $ (5,844) $ (1,407) $ (11,148) $ (5,636) All Other Altera 9 263 (55) 899 Mobileye 78 170 82 422 Other (42) (198) (229) (384) Total all other operating income (loss) $ 45 $ 235 $ (202) $ 937 Total segment operating income (loss) $ (2,462) $ 2,099 $ (1,790) $ 2,224 Intersegment eliminations (79) 5 124 48 Corporate unallocated expenses (6,516) (2,112) (10,424) (4,764) Total operating income (loss) $ (9,057) $ (8) $ (12,090) $ (2,492) Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Acquisition-related costs $ (266) $ (344) $ (796) $ (1,065) Share-based compensation (800) (772) (2,759) (2,433) Restructuring and other charges 1 (5,622) (816) (6,913) (1,080) Other 172 (180) 44 (186) Total corporate unallocated expenses $ (6,516) $ (2,112) $ (10,424) $ (4,764)

Noncontrolling Interest (Tables

Noncontrolling Interest (Tables)	9 Months Ended
Noncontrolling Interest (Tables)	Sep. 28, 2024
Noncontrolling Interest [Abstract]
Noncontrolling Interests	Sep 28, 2024 Dec 30, 2023 ($ In Millions) Non-Controlling Interests Non-Controlling Ownership % Non-Controlling Interests Non-Controlling Ownership % Ireland SCIP $ 51 49 % $ — — % Arizona SCIP 3,518 49 % 2,359 49 % Mobileye 1,617 12 % 1,838 12 % IMS Nanofabrication 146 32 % 178 32 % Total non-controlling interests $ 5,332 $ 4,375

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Sep. 28, 2024
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended Nine Months Ended (In Millions, Except Per Share Amounts) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Net income (loss) $ (16,989) $ 310 $ (19,080) $ (985) Less: net income (loss) attributable to non-controlling interests (350) 13 (450) (5) Net income (loss) attributable to Intel $ (16,639) $ 297 $ (18,630) $ (980) Weighted average shares of common stock outstanding—basic 4,292 4,202 4,267 4,180 Dilutive effect of employee equity incentive plans — 27 — — Weighted average shares of common stock outstanding—diluted 4,292 4,229 4,267 4,180 Earnings (loss) per share attributable to Intel—basic $ (3.88) $ 0.07 $ (4.37) $ (0.23) Earnings (loss) per share attributable to Intel—diluted $ (3.88) $ 0.07 $ (4.37) $ (0.23)

Other Financial Statement Det_2

Other Financial Statement Details (Tables)	9 Months Ended
Other Financial Statement Details (Tables)	Sep. 28, 2024
Other Financial Statement Details [Abstract]
Schedule of Inventory, Current [Table Text Block]	(In Millions) Sep 28, 2024 Dec 30, 2023 Raw materials $ 1,434 $ 1,166 Work in process 6,971 6,203 Finished goods 3,657 3,758 Total inventories $ 12,062 $ 11,127
Interest and Other, Net [Table Text Block]	Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Interest income $ 340 $ 332 $ 983 $ 979 Interest expense (248) (204) (800) (611) Other, net 38 19 172 144 Total interest and other, net $ 130 $ 147 $ 355 $ 512

Restructuring and Other Charg_2

Restructuring and Other Charges (Tables)	9 Months Ended
Restructuring and Other Charges (Tables)	Sep. 28, 2024
Restructuring and Related Activities [Abstract]
Schedule of Restructuring and Other Charges	Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Employee severance and benefit arrangements $ 2,193 $ 59 $ 2,487 $ 191 Litigation charges and other 36 757 814 854 Asset impairment charges 3,393 — 3,612 35 Total restructuring and other charges $ 5,622 $ 816 $ 6,913 $ 1,080

Income Taxes (Tables)

Income Taxes (Tables)	9 Months Ended
Income Taxes (Tables)	Sep. 28, 2024
Income Tax Disclosure [Abstract]
Schedule of Income before Income Tax, Provision for Income Tax and Effective Tax Rate	Three Months Ended Nine Months Ended ($ In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Income (loss) before taxes $ (9,086) $ (52) $ (11,809) $ (2,026) Provision for (benefit from) taxes $ 7,903 $ (362) $ 7,271 $ (1,041) Effective tax rate (87.0) % 696.2 % (61.6) % 51.4 %

Investments (Tables)

Investments (Tables)	9 Months Ended
Investments (Tables)	Sep. 28, 2024
Investments, Debt and Equity Securities [Abstract]
Investments Classified by Contractual Maturity Date [Table Text Block]	The fair value of marketable debt investments, by contractual maturity, as of September 28, 2024, was as follows: (In Millions) Fair Value Due in 1 year or less $ 7,508 Due in 1–2 years 2,322 Due in 2–5 years 6,537 Due after 5 years 215 Instruments not due at a single maturity date 1 3,544 Total $ 20,126 1
Investment [Table Text Block]	(In Millions) Sep 28, 2024 Dec 30, 2023 Marketable equity securities 1 $ 980 $ 1,194 Non-marketable equity securities 4,513 4,630 Equity method investments 3 5 Total $ 5,496 $ 5,829 1 Most of our marketable equity securities are subject to trading-volume or market-based restrictions, which limit the number of shares we may sell in a specified period of time, impacting our ability to liquidate these investments. Certain of the trading volume restrictions generally apply for as long as we own more than 1% of the outstanding shares. Market-based restrictions result from the rules of the respective exchange.
Gain (Loss) on Securities [Table Text Block]	The components of gains (losses) on equity investments, net for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Ongoing mark-to-market adjustments on marketable equity securities $ (51) $ (267) $ (185) $ (164) Observable price adjustments on non-marketable equity securities — 7 49 17 Impairment charges (110) (53) (269) (127) Sale of equity investments and other 1 2 122 331 228 Total gains (losses) on equity investments, net $ (159) $ (191) $ (74) $ (46) 1 Sale of equity investments and other includes initial fair value adjustments recorded upon a security becoming marketable, realized gains (losses) on sales of non-marketable equity investments and equity method investments, and our share of equity method investee gains (losses) and distributions.

Fair Value (Tables)

Fair Value (Tables)	9 Months Ended
Fair Value (Tables)	Sep. 28, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Sep 28, 2024 Dec 30, 2023 Fair Value Measured and Recorded at Reporting Date Using Fair Value Measured and Recorded at Reporting Date Using (In Millions) Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total Assets Cash equivalents: Corporate debt $ — $ 213 $ — $ 213 $ — $ 769 $ — $ 769 Financial institution instruments¹ 3,415 1,197 — 4,612 2,241 835 — 3,076 Reverse repurchase agreements — 3,295 — 3,295 — 2,554 — 2,554 Short-term investments: Corporate debt — 5,777 — 5,777 — 6,951 — 6,951 Financial institution instruments¹ 129 3,301 — 3,430 33 4,215 — 4,248 Government debt² 20 6,074 — 6,094 — 6,756 — 6,756 Other current assets: Derivative assets 261 653 — 914 366 809 — 1,175 Marketable equity securities 980 — — 980 1,194 — — 1,194 Other long-term assets: Derivative assets — 5 — 5 — 21 — 21 Total assets measured and recorded at fair value $ 4,805 $ 20,515 $ — $ 25,320 $ 3,834 $ 22,910 $ — $ 26,744 Liabilities Other accrued liabilities: Derivative liabilities $ — $ 457 $ 96 $ 553 $ — $ 541 $ 99 $ 640 Other long-term liabilities: Derivative liabilities — 212 — 212 — 479 — 479 Total liabilities measured and recorded at fair value $ — $ 669 $ 96 $ 765 $ — $ 1,020 $ 99 $ 1,119 1 Level 1 investments consist of money market funds. Level 2 investments consist primarily of certificates of deposit, time deposits, commercial paper, notes, and bonds issued by financial institutions. 2 Level 1 investments consist of US Treasury securities. Level 2 investments consist primarily of non-US government debt.

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
Derivative Financial Instruments (Tables)	Sep. 28, 2024
Derivative [Line Items]
Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]	Total gross notional amounts for outstanding derivatives (recorded at fair value) at the end of each period were as follows: (In Millions) Sep 28, 2024 Dec 30, 2023 Foreign currency contracts $ 28,674 $ 30,064 Interest rate contracts 18,105 18,363 Other 2,539 2,103 Total $ 49,318 $ 50,530
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]	Fair Value of Derivative Instruments in the Consolidated Condensed Balance Sheets Sep 28, 2024 Dec 30, 2023 (In Millions) Assets 1 Liabilities 2 Assets 1 Liabilities 2 Derivatives designated as hedging instruments: Foreign currency contracts 3 $ 290 $ 54 $ 255 $ 142 Interest rate contracts — 353 — 578 Total derivatives designated as hedging instruments $ 290 $ 407 $ 255 $ 720 Derivatives not designated as hedging instruments: Foreign currency contracts 3 $ 224 $ 252 $ 314 $ 363 Interest rate contracts 144 106 261 36 Equity contracts 261 — 366 — Total derivatives not designated as hedging instruments $ 629 $ 358 $ 941 $ 399 Total derivatives $ 919 $ 765 $ 1,196 $ 1,119 1 Derivative assets are recorded as other assets, current and long-term. 2 Derivative liabilities are recorded as other liabilities, current and long-term. 3 A substantial majority of these instruments mature within 12 months. The amounts recorded on the Consolidated Condensed Balance Sheets related to cumulative basis adjustments for fair value hedges for each period were as follows: Line Item in the Consolidated Condensed Balance Sheets in Which the Hedged Item is Included Carrying Amount of the Hedged Item Assets/(Liabilities) Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities) (In Millions) Sep 28, 2024 Dec 30, 2023 Sep 28, 2024 Dec 30, 2023 Long-term debt $ (11,644) $ (11,419) $ 353 $ 578
Offsetting Assets [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 767 $ — $ 767 $ (319) $ (448) $ — Reverse repurchase agreements 3,295 — 3,295 — (3,295) — Total assets $ 4,062 $ — $ 4,062 $ (319) $ (3,743) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 737 $ — $ 737 $ (319) $ (331) $ 87 Total liabilities $ 737 $ — $ 737 $ (319) $ (331) $ 87 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Offsetting Liabilities [Table Text Block]	Agreements subject to master netting arrangements with various counterparties, and cash and non-cash collateral posted under such agreements at the end of each period were as follows: Sep 28, 2024 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 767 $ — $ 767 $ (319) $ (448) $ — Reverse repurchase agreements 3,295 — 3,295 — (3,295) — Total assets $ 4,062 $ — $ 4,062 $ (319) $ (3,743) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 737 $ — $ 737 $ (319) $ (331) $ 87 Total liabilities $ 737 $ — $ 737 $ (319) $ (331) $ 87 Dec 30, 2023 Gross Amounts Not Offset in the Balance Sheet (In Millions) Gross Amounts Recognized Gross Amounts Offset in the Balance Sheet Net Amounts Presented in the Balance Sheet Financial Instruments Cash and Non-Cash Collateral Received or Pledged Net Amount Assets: Derivative assets subject to master netting arrangements $ 1,047 $ — $ 1,047 $ (617) $ (430) $ — Reverse repurchase agreements 2,554 — 2,554 — (2,554) — Total assets $ 3,601 $ — $ 3,601 $ (617) $ (2,984) $ — Liabilities: Derivative liabilities subject to master netting arrangements $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95 Total liabilities $ 1,111 $ — $ 1,111 $ (617) $ (399) $ 95
Not Designated as Hedging Instrument
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments not designated as hedging instruments on the Consolidated Condensed Statements of Income for each period were as follows: Three Months Ended Nine Months Ended (In Millions) Location of Gains (Losses) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Foreign currency contracts Interest and other, net $ (344) $ 255 $ 192 $ 467 Interest rate contracts Interest and other, net (127) 85 24 175 Other Various 97 (112) 290 103 Total $ (374) $ 228 $ 506 $ 745
Interest and other, net [Member] \| Fair Value Hedging
Derivative [Line Items]
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance [Table Text Block]	The effects of derivative instruments designated as fair value hedges, recognized in interest and other, net for each period were as follows: Gains (Losses) on Derivatives Recognized in Consolidated Condensed Statements of Income Three Months Ended Nine Months Ended (In Millions) Sep 28, 2024 Sep 30, 2023 Sep 28, 2024 Sep 30, 2023 Interest rate contracts $ 345 $ (168) $ 225 $ (189) Hedged items (345) 168 (225) 189 Total $ — $ — $ — $ —

Operating Segments - Narrative

Operating Segments - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 28, 2024	Mar. 30, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Revenue from external customers	$ 13,284		$ 14,158	$ 38,841	$ 38,822
Goodwill impairment loss	2,800	$ 222		3,000
Operating segments
Segment Reporting Information [Line Items]
Revenue from external customers	17,581		18,577	51,745	51,895
Operating segments \| Intel Foundry
Segment Reporting Information [Line Items]
Revenue from external customers	4,352		4,732	13,041	13,735
Operating segments \| Intel Foundry \| Assembly and Test
Segment Reporting Information [Line Items]
Revenue from external customers	67		312	171	661
Operating segments \| Other
Segment Reporting Information [Line Items]
Revenue from external customers	$ 142		$ 187	$ 503	$ 470

Operating Segments - Net Revenu

Operating Segments - Net Revenue and Operating Income (Loss) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Oct. 01, 2022
Segment Reporting Information [Line Items]
Net revenue	$ 13,284	$ 14,158	$ 38,841	$ 38,822
Operating income (loss)	(9,057)	(8)	(12,090)	(2,492)
Operating segments
Segment Reporting Information [Line Items]
Net revenue	17,581	18,577	51,745	51,895
Operating income (loss)	(2,462)	2,099	(1,790)	2,224
Operating segments \| Intel Products
Segment Reporting Information [Line Items]
Net revenue	12,190	12,393	35,922	33,849
Operating income (loss)	3,337	3,271	9,560	6,923
Operating segments \| Client Computing
Segment Reporting Information [Line Items]
Net revenue	7,330	7,867	22,273	20,414
Operating income (loss)	2,722	2,780	7,864	5,946
Operating segments \| Client Computing \| Desktop
Segment Reporting Information [Line Items]
Net revenue	2,070	2,753	7,058	7,002
Operating segments \| Client Computing \| Notebook
Segment Reporting Information [Line Items]
Net revenue	4,888	4,503	14,049	11,806
Operating segments \| Client Computing \| Other
Segment Reporting Information [Line Items]
Net revenue	372	611	1,166	1,606
Operating segments \| Datacenter and AI
Segment Reporting Information [Line Items]
Net revenue	3,349	3,076	9,430	9,132
Operating income (loss)	347	391	1,105	882
Operating segments \| Network and Edge
Segment Reporting Information [Line Items]
Net revenue	1,511	1,450	4,219	4,303
Operating income (loss)	268	100	591	95
Operating segments \| Intel Foundry
Segment Reporting Information [Line Items]
Net revenue	4,352	4,732	13,041	13,735
Operating income (loss)	(5,844)		(11,148)	(5,636)	$ (1,407)
Operating segments \| All Other
Segment Reporting Information [Line Items]
Net revenue	1,039	1,452	2,782	4,311
Operating income (loss)	45	235	(202)	937
Operating segments \| Altera
Segment Reporting Information [Line Items]
Net revenue	412	735	1,115	2,399
Operating income (loss)	9	263	(55)	899
Operating segments \| Mobileye
Segment Reporting Information [Line Items]
Net revenue	485	530	1,164	1,442
Operating income (loss)	78	170	82	422
Operating segments \| Other
Segment Reporting Information [Line Items]
Net revenue	142	187	503	470
Operating income (loss)	(42)	(198)	(229)	(384)
Intersegment eliminations
Segment Reporting Information [Line Items]
Net revenue	(4,297)	(4,419)	(12,904)	(13,073)
Operating income (loss)	(79)	5	124	48
Corporate unallocated expenses
Segment Reporting Information [Line Items]
Operating income (loss)	$ (6,516)	$ (2,112)	$ (10,424)	$ (4,764)

Operating Segments - Corporate

Operating Segments - Corporate Unallocated Expenses (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Segment Reporting Information [Line Items]
Restructuring and other charges	$ (5,622)	$ (816)	$ (6,913)	$ (1,080)
Operating income (loss)	(9,057)	(8)	(12,090)	(2,492)
Corporate unallocated expenses
Segment Reporting Information [Line Items]
Acquisition-related costs	(266)	(344)	(796)	(1,065)
Share-based compensation	(800)	(772)	(2,759)	(2,433)
Restructuring and other charges	(5,622)	(816)	(6,913)	(1,080)
Other	172	(180)	44	(186)
Operating income (loss)	$ (6,516)	$ (2,112)	$ (10,424)	$ (4,764)

Non-Controlling Interests - Com

Non-Controlling Interests - Components (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Noncontrolling Interest [Line Items]
Non-controlling interest	$ 5,332	$ 4,375
Ireland SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest	51	0
Arizona SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest	3,518	2,359
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest	1,617	1,838
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-controlling interest	$ 146	$ 178
Ireland SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	49%	0%
Arizona SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	49%	49%
Mobileye
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	12%	12%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	32%	32%

Non-Controlling Interests - Nar

Non-Controlling Interests - Narrative (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 28, 2024	Jun. 29, 2024	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares			$ 0	$ 2,423
Assets	$ 193,542		193,542		$ 191,572
Ireland SCIP
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares	$ 11,000
Percentage of factory output with the right to purchase	100%
Variable Interest Entity, Primary Beneficiary \| Asset Pledged as Collateral
Noncontrolling Interest [Line Items]
Assets	$ 9,300		9,300		$ 4,800
Mobileye
Noncontrolling Interest [Line Items]
Conversion of stock, shares converted (in shares)		38,500,000
Conversion of stock, shares converted, percentage of outstanding shares		0.05
Shares issued per share (in dollars per share)					$ 42
Net proceeds		$ 1,600
Mobileye \| Capital in excess of par value
Noncontrolling Interest [Line Items]
Net proceeds from partner contributions		663
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Proceeds from sales of subsidiary shares		1,400
IMS Nanofabrication \| Capital in excess of par value
Noncontrolling Interest [Line Items]
Net proceeds from partner contributions		$ 958
Semiconductor Co-Investment Program, Construction Costs \| Intel and Brookfield
Noncontrolling Interest [Line Items]
Unrecognized commitment	$ 29,000		$ 29,000
Ireland SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	49%		49%		0%
Arizona SCIP
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	49%		49%		49%
Percentage of factory output with the right to purchase			100%
IMS Nanofabrication
Noncontrolling Interest [Line Items]
Non-controlling interest percent held by parent	32%		32%		32%
Ownership percentage sold		32%
IMS Nanofabrication \| Bain Capital Special Situations
Noncontrolling Interest [Line Items]
Ownership percentage sold		20%
IMS Nanofabrication \| TSMC
Noncontrolling Interest [Line Items]
Ownership percentage sold		10%

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Earnings Per Share [Abstract]
Net income (loss)	$ (16,989)	$ 310	$ (19,080)	$ (985)
Less: net income (loss) attributable to non-controlling interests	(350)	13	(450)	(5)
Net income (loss) attributable to Intel	$ (16,639)	$ 297	$ (18,630)	$ (980)
Weighted average shares of common stock outstanding—basic	4,292	4,202	4,267	4,180
Dilutive effect of employee equity incentive plans (shares)	0	27	0	0
Weighted average shares of common stock outstanding—diluted	4,292	4,229	4,267	4,180
Earnings per share - Basic (in dollars per share)	$ (3.88)	$ 0.07	$ (4.37)	$ (0.23)
Earnings per share - Diluted (in dollars per share)	$ (3.88)	$ 0.07	$ (4.37)	$ (0.23)
Anti-dilutive shares excluded from the computation of diluted earnings per share (in shares)	160	0	0	0

Other Financial Statement Det_3

Other Financial Statement Details - Accounts Receivable (Details) $ in Billions	9 Months Ended
	Sep. 28, 2024 USD ($)
Other Financial Statement Details [Abstract]
Accounts receivable sold	$ 1.5

Other Financial Statement Det_4

Other Financial Statement Details - Inventories (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Other Financial Statement Details [Abstract]
Raw materials	$ 1,434	$ 1,166
Work in process	6,971	6,203
Finished goods	3,657	3,758
Total inventories	$ 12,062	$ 11,127

Other Financial Statement Det_5

Other Financial Statement Details - Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 28, 2024	Sep. 28, 2024	Sep. 30, 2023
Property, Plant and Equipment [Line Items]
Impairment of property, plant and equipment	$ 2,100
Depreciation		$ 7,651	$ 5,753
Value of Manufacturing Asset Portfolio
Property, Plant and Equipment [Line Items]
Depreciation	945
2024 Restructuring Program
Property, Plant and Equipment [Line Items]
Impairment of assets to be disposed of	$ 442

Other Financial Statement Det_6

Other Financial Statement Details - Other Accrued Liabilities (Details) - USD ($) $ in Billions	Sep. 28, 2024	Dec. 30, 2023
Other Financial Statement Details [Abstract]
Deferred compensation	$ 3.2	$ 2.9

Other Financial Statement Det_7

Other Financial Statement Details - Interest and Other, Net (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Other Financial Statement Details [Abstract]
Interest income	$ 340	$ 332	$ 983	$ 979
Interest expense	(248)	(204)	(800)	(611)
Other, net	38	19	172	144
Total interest and other, net	130	147	355	512
Interest Costs Capitalized	$ 392	$ 395	$ 1,100	$ 1,100

Restructuring and Other Charg_3

Restructuring and Other Charges - Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Restructuring and Related Activities [Abstract]
Employee severance and benefit arrangements	$ 2,193	$ 59	$ 2,487	$ 191
Litigation charges and other	36	757	814	854
Asset impairment charges	3,393	0	3,612	35
Total restructuring and other charges	$ 5,622	$ 816	$ 6,913	$ 1,080

Restructuring and Other Charg_4

Restructuring and Other Charges - Narrative (Details) - USD ($) $ in Millions	3 Months Ended				9 Months Ended
	Sep. 28, 2024	Jun. 29, 2024	Mar. 30, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Loss Contingencies [Line Items]
Employee severance and benefit arrangements	$ 2,193			$ 59	$ 2,487	$ 191
Litigation charges and other	36			757	814	$ 854
Goodwill impairment charge	2,800		$ 222		3,000
Impairment of acquired intangible assets	108
Tower
Loss Contingencies [Line Items]
Litigation charges and other				353
2024 Restructuring Program
Loss Contingencies [Line Items]
Expected restructuring charges	3,000				3,000
Cumulative restructuring cost	2,800				2,800
Employee severance and benefit arrangements	2,200
Impairment of assets to be disposed of	442
Impairment of operating leased assets	86
2024 Restructuring Program \| Other Long-Term Assets
Loss Contingencies [Line Items]
Impairment of operating leased assets	$ 72
Streamline Operations
Loss Contingencies [Line Items]
Employee severance and benefit arrangements					$ 294
R2 Semiconductor Patent Litigation
Loss Contingencies [Line Items]
Litigation charges and other		$ 780
EC Fine
Loss Contingencies [Line Items]
Litigation charges and other				$ 401

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Income Tax Disclosure [Abstract]
Income (loss) before taxes	$ (9,086)	$ (52)	$ (11,809)	$ (2,026)
Provision for (benefit from) taxes	$ 7,903	$ (362)	$ 7,271	$ (1,041)
Effective tax rate	(87.00%)	696.20%	(61.60%)	51.40%

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Sep. 28, 2024	Sep. 28, 2024	Dec. 30, 2023
Other Long-Term Liabilities
Valuation Allowance [Line Items]
Deferred income taxes	$ 1,700	$ 1,700	$ 186
Other Long-Term Assets
Valuation Allowance [Line Items]
Deferred Income Tax Assets, Net	634	634	$ 5,500
United States
Valuation Allowance [Line Items]
Valuation allowance increase	$ 9,900	$ 9,900

Investments - Short-term Invest

Investments - Short-term Investments (Details) - USD ($)	3 Months Ended		9 Months Ended
Investments - Short-term Investments (Details) - USD ($)	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Debt Securities, Realized Gain (Loss)	$ (406,000,000)	$ (329,000,000)	$ (195,000,000)	$ (336,000,000)
Debt Securities, Available-for-sale, Amortized Cost	5,200,000,000		5,200,000,000		$ 4,700,000,000
Available-for-sale Securities
Schedule Of Trading Securities And Other Trading Assets [Line Items]
Derivative, Amount of Hedged Item	$ 14,900,000,000		$ 14,900,000,000		$ 17,100,000,000

Investments - Available-for-Sal

Investments - Available-for-Sale Debt Investments (Details) $ in Millions	Sep. 28, 2024 USD ($)
Investments, Debt and Equity Securities [Abstract]
Due in 1 year or less	$ 7,508
Due in 1–2 years	2,322
Due in 2–5 years	6,537
Due after 5 years	215
Instruments not due at a single maturity date	3,544
Debt Securities, Available-for-Sale, Total	$ 20,126

Investments - Equity Investment

Investments - Equity Investments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	$ 980		$ 980		$ 1,194
Cost Method Investments	4,513		4,513		4,630
Equity Method Investments	3		3		5
Equity Investments	5,496		$ 5,496		$ 5,829
Marketable equity securities threshold percentage of shares owned resulting in trading volume restrictions			1%
Mark to market on marketable equity securities1	(51)	$ (267)	$ (185)	$ (164)
Observable price adjustments on non-marketable	0	7	49	17
Impairments	(110)	(53)	(269)	(127)
Other Net Equity Investments	2	122	331	228
Gain (Loss) on Investments	$ (159)	$ (191)	$ (74)	$ (46)

Investments - Equity Investme_2

Investments - Equity Investments, Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Schedule of Equity Method Investments [Line Items]
Special dividend recognized in sale of equity investments and other	$ 2	$ 122	$ 331	$ 228

Investments - Bejing Unisoc Tec

Investments - Bejing Unisoc Technology (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023
Schedule of Investments [Line Items]
Gains (losses) on equity investments, net	$ (159)	$ (191)	$ (74)	$ (46)

Divestitures (Details)

Divestitures (Details) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Business Acquisition [Line Items]
Receivable recorded in other current assets	$ 6,868	$ 3,706
NAND Memory Business Divestiture \| Affiliated Entity
Business Acquisition [Line Items]
Receivable recorded in other current assets	92	$ 145
NAND Memory Business
Business Acquisition [Line Items]
Noncurrent receivable	2,000
Maximum exposure annually	500
Maximum exposure	$ 1,500

Goodwill (Details)

Goodwill (Details)	3 Months Ended		9 Months Ended
Goodwill (Details)	Sep. 28, 2024 USD ($)	Mar. 30, 2024 USD ($)	Sep. 28, 2024 USD ($)	Dec. 30, 2023 USD ($)
Goodwill [Line Items]
Goodwill impairment charge	$ 2,800,000,000	$ 222,000,000	$ 3,000,000,000
Goodwill	$ 24,680,000,000		24,680,000,000	$ 27,591,000,000
Measurement Input, Discount Rate
Goodwill [Line Items]
Goodwill measurement input increase	0.01
Intel Foundry
Goodwill [Line Items]
Goodwill	$ 0		$ 0

Borrowings - Narrative (Details

Borrowings - Narrative (Details) - USD ($)	3 Months Ended	9 Months Ended
Borrowings - Narrative (Details) - USD ($)	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Jun. 29, 2024	Dec. 30, 2023
Debt Instrument [Line Items]
Commercial paper borrowed		$ 7,349,000,000	$ 0
Commercial paper settled in cash		7,349,000,000	3,944,000,000
Commercial paper outstanding		0			$ 0
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity		10,000,000,000
Arizona Bonds due in 2049
Debt Instrument [Line Items]
Face amount of debt		$ 438,000,000
Interest rate		4%
Senior Notes, 5.00%, Due 2031
Debt Instrument [Line Items]
Interest rate				5%
Senior Notes, 5.15%, Due 2034
Debt Instrument [Line Items]
Interest rate				5.15%
Senior Notes, 5.60%, Due 2054
Debt Instrument [Line Items]
Interest rate				5.60%
Revolving Credit Facility \| Variable Rate Revolving Credit Facility
Debt Instrument [Line Items]
Term of debt	5 years
Maximum borrowing capacity	$ 7,000,000,000		7,000,000,000		5,000,000,000
Variable rate revolving credit facility		$ 0
Senior Notes
Debt Instrument [Line Items]
Face amount of debt				$ 2,600,000,000
Senior Notes \| Senior Notes, 5.00%, Due 2031
Debt Instrument [Line Items]
Face amount of debt				500,000,000
Senior Notes \| Senior Notes, 5.15%, Due 2034
Debt Instrument [Line Items]
Face amount of debt				900,000,000
Senior Notes \| Senior Notes, 5.60%, Due 2054
Debt Instrument [Line Items]
Face amount of debt				$ 1,200,000,000
Line of Credit \| Credit Facility Agreement
Debt Instrument [Line Items]
Term of debt	364 days
Maximum borrowing capacity	$ 8,000,000,000		$ 8,000,000,000		$ 5,000,000,000
Variable rate revolving credit facility		$ 0

Fair Value (Detail)

Fair Value (Detail) - USD ($) $ in Millions	Sep. 28, 2024	Dec. 30, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	$ 3,295	$ 2,554
Derivative assets, Fair Value Disclosure	767	1,047
Derivative liabilities, Fair Value Disclosure	737	1,111
Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	25,320	26,744
Liabilities, Fair Value Disclosure	765	1,119
Fair Value, Nonrecurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Grants & loans Receivable, Reverse repurchase agreements, CV	1,100	559
Marketable Equity Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	980	1,194
Cash Equivalents \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	3,295	2,554
Cash Equivalents \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	213	769
Cash Equivalents \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	4,612	3,076
Short-Term Investments \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,777	6,951
Short-Term Investments \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,430	4,248
Short-Term Investments \| Government Debt \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,094	6,756
Other Current Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	914	1,175
Other Long-Term Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	5	21
Other Accrued Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	553	640
Other Long-Term Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	212	479
Level 1 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	4,805	3,834
Liabilities, Fair Value Disclosure	0	0
Level 1 \| Marketable Equity Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	980	1,194
Level 1 \| Cash Equivalents \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 1 \| Cash Equivalents \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 \| Cash Equivalents \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,415	2,241
Level 1 \| Short-Term Investments \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 1 \| Short-Term Investments \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	129	33
Level 1 \| Short-Term Investments \| Government Debt \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	20	0
Level 1 \| Other Current Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	261	366
Level 1 \| Other Long-Term Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 1 \| Other Accrued Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 1 \| Other Long-Term Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of issued debt	46,000	47,600
Level 2 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	20,515	22,910
Liabilities, Fair Value Disclosure	669	1,020
Level 2 \| Marketable Equity Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 2 \| Cash Equivalents \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	3,295	2,554
Level 2 \| Cash Equivalents \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	213	769
Level 2 \| Cash Equivalents \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	1,197	835
Level 2 \| Short-Term Investments \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	5,777	6,951
Level 2 \| Short-Term Investments \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	3,301	4,215
Level 2 \| Short-Term Investments \| Government Debt \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	6,074	6,756
Level 2 \| Other Current Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	653	809
Level 2 \| Other Long-Term Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	5	21
Level 2 \| Other Accrued Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	457	541
Level 2 \| Other Long-Term Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	212	479
Level 3 \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets, Fair Value Disclosure	0	0
Liabilities, Fair Value Disclosure	96	99
Level 3 \| Marketable Equity Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Cash Equivalents \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Reverse repurchase agreements	0	0
Level 3 \| Cash Equivalents \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Cash Equivalents \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Short-Term Investments \| Corporate Debt Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Short-Term Investments \| Fixed Income Securities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Short-Term Investments \| Government Debt \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Investments, Fair Value Disclosure	0	0
Level 3 \| Other Current Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 \| Other Long-Term Assets \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets, Fair Value Disclosure	0	0
Level 3 \| Other Accrued Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	96	99
Level 3 \| Other Long-Term Liabilities \| Fair Value, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities, Fair Value Disclosure	$ 0	$ 0

Derivative Financial Instrume_3

Derivative Financial Instruments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Notional Disclosures [Abstract]
Notional amount	$ 49,318		$ 49,318		$ 50,530
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	767		767		1,047
Derivative Assets Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0		0
Derivative Assets Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	767		767		1,047
Derivative Assets, Financial Instruments Not Offset in the Balance Sheet	(319)		(319)		(617)
Derivative Assets, Cash Collateral Not Offset in the Balance Sheet	(448)		(448)		(430)
Derivative Assets Subject to Master Netting Arrangements, Net Amount	0		0		0
Reverse Repurchase Agreements, Gross Amounts Recognized	3,295		3,295		2,554
Reverse Repurchase Agreements, Gross Amounts Offset In The Balance Sheet	0		0		0
Reverse Repurchase Agreements, Net Amount Presented in the Balance Sheet	3,295		3,295		2,554
Reverse Repurchase Agreements, Financial Instruments Not Offset in the Balance Sheet	0		0		0
Reverse Repurchase Agreements, Cash Collateral Not Offset in the Balance Sheet	(3,295)		(3,295)		(2,554)
Reverse Repurchase Agreements, Net Amount	0		0		0
Total Assets, Gross Amounts Recognized	4,062		4,062		3,601
Total Assets, Gross Amounts Offset in the Balance Sheet	0		0		0
Total Assets, Net Amounts Presented in the Balance Sheet	4,062		4,062		3,601
Total Assets, Financial Instruments, Not Offset in the Balance Sheet	(319)		(319)		(617)
Total Assets, Cash and Non Cash Collateral, Not Offset in the Balance Sheet	(3,743)		(3,743)		(2,984)
Total Assets, Net Amount	0		0		0
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	737		737		1,111
Derivative Liabilities Subject to Master Netting Arrangements, Gross Amounts Offset in the Balance Sheet	0		0		0
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount Presented in the Balance Sheet	737		737		1,111
Derivative Liabilities, Financial Instruments Not Offset in the Balance Sheet	(319)		(319)		(617)
Derivative Liabilities, Cash Collateral Not Offset in the Balance Sheet	(331)		(331)		(399)
Derivative Liabilities Subject to Master Netting Arrangements, Net Amount	87		87		95
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge	(345)	$ 168	(225)	$ 189
Net Change In Unrealized Gain (Loss) Recognized In Income Statement On Fair Value Hedging Instruments And On Hedged Item In Fair Value Hedge	0	0	0	0
Long-term Debt
Fair Value Hedges, Net, Total [Abstract]
Carrying Amount of the Hedged Item Assets/(Liabilities)	(11,644)		(11,644)		(11,419)
Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount Assets/(Liabilities)	353		353		578
Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	919		919		1,196
Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	765		765		1,119
Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	290		290		255
Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	407		407		720
Not Designated as Hedging Instrument
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	(374)	228	506	745
Not Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	629		629		941
Not Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	358		358		399
Foreign currency contracts
Notional Disclosures [Abstract]
Notional amount	28,674		28,674		30,064
Derivative Instruments, Gain (Loss) Reclassified from Accumulated OCI into Income, Effective Portion, Net [Abstract]
Before-tax net gains (losses) attributed to cash flow hedges, recognized in other comprehensive income (loss)	609	454	49	646
Foreign currency contracts \| Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	290		290		255
Foreign currency contracts \| Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	54		54		142
Foreign currency contracts \| Not Designated as Hedging Instrument
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	(344)	255	192	467
Foreign currency contracts \| Not Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	224		224		314
Foreign currency contracts \| Not Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	252		252		363
Interest rate contracts
Notional Disclosures [Abstract]
Notional amount	18,105		18,105		18,363
Effect of Fair Value Hedges on Results of Operations [Abstract]
Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments	345	(168)	225	(189)
Interest rate contracts \| Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	0		0		0
Interest rate contracts \| Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	353		353		578
Interest rate contracts \| Not Designated as Hedging Instrument
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	(127)	85	24	175
Interest rate contracts \| Not Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	144		144		261
Interest rate contracts \| Not Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	106		106		36
Other
Notional Disclosures [Abstract]
Notional amount	2,539		2,539		2,103
Other \| Not Designated as Hedging Instrument
Derivative Instruments Not Designated as Hedging Instruments [Abstract]
Gains (Losses) Recognized in Income On Derivatives	97	$ (112)	290	$ 103
Other \| Not Designated as Hedging Instrument \| Assets
Offsetting Derivative Assets [Abstract]
Derivative Assets, Fair Value, Gross Amounts	261		261		366
Other \| Not Designated as Hedging Instrument \| Liabilities
Offsetting Derivative Liabilities [Abstract]
Derivative Liabilities, Fair Value, Gross Amounts	0		0		$ 0
Interest Rate Swap \| Long-term Debt \| Fair Value Hedging
Notional Disclosures [Abstract]
Derivative, Amount of Hedged Item	$ 12,000		$ 12,000

Contingencies (Detail)

Contingencies (Detail) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
Contingencies (Detail) - USD ($) $ in Millions	Sep. 28, 2024	Jun. 29, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023
Loss Contingencies [Line Items]
Litigation charges and other	$ 36		$ 757	$ 814	$ 854
Finance lease prepayments				0	$ 96
VLSI Litigation
Loss Contingencies [Line Items]
Litigation charges accrued	1,000			1,000
R2 Semiconductor Patent Litigation
Loss Contingencies [Line Items]
Litigation charges and other		$ 780
EC Fine
Loss Contingencies [Line Items]
Litigation charges accrued	$ 401			$ 401
Litigation charges and other			$ 401
Arizona SCIP
Loss Contingencies [Line Items]
Non-controlling interest percent held by parent	49%			49%		49%